Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma.

ABSTRACT:

Background

Anthracycline-containing regimens, namely cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOEP (CHOP + etoposide), represent the current standard of care for patients with newly diagnosed peripheral T-cell lymphomas (PTCLs), although responses are unsatisfactory. In this study, we investigated the pathways able to mitigate the sensitivity to CHOP-based regimens in preclinical models of T-cell lymphoma (TCL) to select agents for the development of CHOP-based drug combinations.

Methods

We performed gene expression profiling of malignant T-cell lines exposed to CHOEP; flow cytometry was employed to study the effects of drug combinations on cell viability, cell cycle distribution, apoptosis and mitochondrial membrane depolarisation. Western blot a

SUBMITTER: Magni M 

PROVIDER: S-EPMC6889385 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature